StockWatch
·

Excelsoft Technologies Ltd Q2 FY27 Results

EXCELSOFTQ2 FY27 Results
Filing
Result:Weak· Market: Down#Margin squeeze

Outlook: Cautiously Optimistic · Guidance: Maintained

MetricValue (₹ Cr)Q1 FY27Q2 FY26
Revenue80.900.8%25.2%
Total Income86.630.6%26.2%
Expenditure75.451.6%38.9%
PBT11.175.5%21.8%
Net Profit8.2810.3%22.0%
OPM16.35%0.11pp10.75pp
NPM9.55%1.17pp5.91pp
EPS0.7210.0%31.4%
View full financials

Revenue grew a healthy 25.2% YoY but PAT fell 22% as OPM compressed sharply from 27.1% to 16.35%, a clear margin squeeze that outweighs the top-line growth for an IT services name.

EXCELSOFT TECHNOLOGIES LTD · Q2 FY-2027 · THE VERDICT

25% Revenue Growth Masks a 22% Profit Collapse; Margin Recovery Still Unproven

Excelsoft delivered strong topline momentum (+25.2% YoY) and a ₹1,200 Cr pipeline, but profitability fell off a cliff — PAT down 22% despite guidance for margin recovery. The question is whether ₹20.3 Cr in strategic investments will actually yield the promised 22–25% EBITDA margin, or whether the business model itself has shifted.

12 Nov 2026 · 6 min read
Q2 Revenue

₹80.9 Cr

+25.2% YoY; H1 ₹161.2 Cr, +33.9%

Q2 PAT

₹8.3 Cr

-22% YoY; H1 ₹16.1 Cr, +6.2%

EBITDA margin

16.35%

vs 29.3% prior year; guided 22–25%

Strategic investments (FY27)

₹20.3 Cr

Sales teams, talent, product dev; charged to P&L

The quarter embodies a contradiction: Excelsoft is growing the top line hard (+25.2% YoY, H1 tracking to ₹350 Cr full-year target) yet profitability is evaporating. On a reported basis, PAT fell ₹2.5 Cr (-22% YoY) even as revenue grew ₹16.3 Cr. The company attributes the margin collapse entirely to ₹20.3 Cr in strategic investments — sales team deployment across US, UK, Middle East, Canada; talent hiring; AI product development. The claim is mechanical: spend first, revenue later. The risk is that this may be permanent, not temporary.

What management claimed vs. what holds up

  • Revenue growth of 25.2% YoY shows business continues to grow

  • H1 growth at 33.9% demonstrates momentum

  • No structural change in margin profile — decline is investment-driven, not operational

  • Pipeline improved by 20% in recent quarters

  • EBITDA margin to recover to 22–25% once investments yield

Top-line claims hold up completely. Q2 revenue ₹80.9 Cr vs ₹64.61 Cr prior year = exactly 25.2% growth. H1 ₹161.2 Cr vs ₹120.3 Cr = exactly 33.9%. The pipeline claim is slightly overstated: management said 20% growth, but actual is ₹1,200 Cr now vs ₹900 Cr at FY26-27 start = 33% growth — higher than stated, a rare management miss in the conservative direction. The margin claim is contradicted by the numbers. Management asserts 'no structural change' and frames the decline as temporary. Yet EBITDA margin fell 13 percentage points (29.3% → 16.35%) — the largest move in either direction would erase this. Management's own prior guidance was 24–25% for FY27; Q2 came in at 16.35%, a 8–9 pp miss. The company now guides 22–25% recovery 'in the next couple of quarters,' but with no evidence of traction yet and ₹20.3 Cr still flowing out, credibility on the 22–25% target is medium at best.

What changed on this call

Pipeline acceleration (positive): ₹300 Cr added to the pipeline in H1 FY27 (₹900 Cr → ₹1,200 Cr). This is a 33% jump and management credibly links it to geographic expansion teams now deployed. This is real and was not emphasized on the prior call. Margin guidance effectively revised downward (negative): Prior guidance on the call was EBITDA margin 24–25% with a prior-year baseline of 30–31%. Q2 delivered 16.35%, and management now calibrates recovery to 22–25%, not the prior 30–31%. This is a silent downgrade: even in recovery, Excelsoft expects permanently lower margins than two quarters ago. AQA revenue timing now uncertain (negative): This assessment platform was guided to contribute ₹12–15 Cr in FY27; customer-side UAT delays and acceptance testing backlog are causing deferral. Program moved to e-marking (98.6% automation) and is working on extraction (handwriting to machine text), but revenue recognition now deferred — exact timing unclear. AI revenue timeline extended (neutral/negative): 16 AI prototypes developed. Management expects 'meaningful AI revenue contribution' in the 'coming quarter' (Q3+) but offers no quantification. This is aspirational without a number. Geographic expansion costs now visible (negative): ₹20.3 Cr investment is now on the P&L (charged to operating expenses), not capitalized. This depresses reported margins and will persist through FY27 end. Prior call did not explicitly quantify this investment or its timing.

The bull-bear ledger

Revenue momentum accelerating: H1 +33.9% YoY, tracking ₹350 Cr FY27 target

PAT is -22% YoY despite 25% revenue growth — profitability disconnected from growth

Pipeline ₹1,200 Cr (33% growth) provides visibility into future order intake

75% revenue from top 5 customers; single loss materially impacts revenue; procurement cycle in large orgs is slow

Education tech segment (60.75% of revenue) growing 41.9% YoY; structural tailwind

ETS (a single customer with 12 divisions) is bulk of education tech; concentration risk poorly managed

Strong cash position (₹407 Cr, no debt) funds ₹20.3 Cr investments without external funding

Cash spent today on investments; ROI timing uncertain (3–6 months stated, vague on volume impact)

Margin recovery to 22–25% is mechanism-driven (investments + pipeline) and reaffirmed by management

Q2 EBITDA margin 16.35% vs 24–25% guided = 8–9 pp miss; recovery credibility weakened; no evidence yet

Operating cash flow ₹34.7 Cr (H1) strong; business generates cash despite P&L pressure

AQA revenue deferred due to customer UAT delays; execution risk in large-org sales cycles

Risks, ranked by how much they should concern a holder

Margin recovery delayed or undelivered

High

Q2 EBITDA margin 16.35% is 8–9 pp below guided 24–25%. If ₹20.3 Cr investments don't yield and margins stay at 16–18%, PAT will remain depressed for quarters. Profitability would be locked in at 40% below prior baselines.

Customer concentration (75% top 5, ETS-heavy)

High

Single large customer loss would crater revenue. ETS has 12 divisions but purchasing decisions are slow and centralized. Concentration to <30% is a 5-year goal; no interim milestones. Macro slowdown in gov procurement (ETS is tied to standardized testing demand) would hit Excelsoft hard.

AQA revenue deferral extends further

Medium

Guided ₹12–15 Cr FY27 contribution; customer UAT delays are already pushing timing. Further delays compress H2 options and lower full-year guidance. Would compound margin miss.

Geographic expansion ROI doesn't materialize

Medium

₹20.3 Cr invested across 4 new geographies (US, UK, Middle East, Canada). Sales team conversion takes 3–6 months; deployment to revenue is 9+ months total. If new geographies don't close deals, capex is wasted and margins stay compressed.

AI revenue ramp slower than promised

Medium

16 prototypes but no named commercial deployments. Management expects 'meaningful revenue' in Q3+ but doesn't quantify. Risk of over-promise and under-deliver (common in AI narratives); if AI doesn't materialize, TAM for new products shrinks.

How the street is reading this

Price action and valuation context: Excelsoft trades at ₹76.36 as of Nov 11, down 46.45% from its all-time high of ₹142.59. The stock is trading below its 20-day SMA (₹78.63), 50-day SMA (₹78.45), and 200-day SMA (₹80.28) — a bearish setup. RSI is neutral at 45.9, not oversold. The stock has rebounded 15% off its 52-week low of ₹66.4, but remains in the lower half of its 52-week range. This is not a panic sell-off; it's a measured, multi-month drift lower reflecting genuine concerns about profitability. Institutional positioning: FII and DII are both reducing exposure. FII holdings dropped 0.25 pp QoQ (1.37% → 1.12%), and DII dropped 0.95 pp (4.05% → 3.10%). Promoter ownership stable at 59.09%. The reduction is quiet but steady — not a flight, but a retreat. This aligns with the fundamental concern: growth without profits is not a long-term holding for institutions. Insider and bulk activity: Bulk deals over the past 6 months show NK Securities Research trading blocks in and out (Sep 09 at ₹76.41 buy/sell, May 22 at ₹97.07 buy/sell). These are likely index rebalancing or derivative hedging, not significant insider positioning. No red flags. The market's own verdict: The price action confirms the fundamental story: growth is real, but profitability risk is material. The 46% drawdown from ATH is steep, but the absence of a panic sell (RSI not deeply oversold, volume normal) suggests the market is waiting for evidence of margin recovery. If Q3 delivers on the 22–25% EBITDA margin target, the stock should recover. If margins stay at 16–18%, further downside is likely.

The debate

What to watch next
  • 1 · Q3 EBITDA margin (the threshold)

    Does it move toward 22–25% or stay at 16–18%? This single number resolves whether the investment thesis holds. If margin stays low, confidence in recovery evaporates and downside risk accelerates.

  • 2 · AQA revenue recognition (acceptance testing clearance)

    When does UAT clear and revenue start flowing? ₹12–15 Cr guided for FY27 is at risk if delays extend past Q4. This is a binary: acceptance clears, or it doesn't.

  • 3 · New customer wins and concentration reduction

    Do geographic expansion sales teams close deals with non-ETS customers? Pipeline grew ₹300 Cr, but *which* customers? If new revenue still comes from ETS divisions or British Council, concentration risk persists. Evidence of new customer logos in Q3 earnings would matter.

Excelsoft is not in distress — cash flow is healthy, revenue is growing, and the long-term narrative (education tech, geographic expansion, AI) is intact. But the gap between the reported quarter and the guided margin is too large to overlook. The company must prove it can invest and grow *and* manage margins, not one or the other. The next two quarters will determine whether this is a temporary margin trough or a permanent shift in the business model. Until margin recovery is visible, the hold rating stands.

The number to track: Q3 EBITDA margin. If it's >20%, the stock should recover. If it stays <18%, the 46% drawdown from ATH will look like early innings, not a buying opportunity.

Informational and educational content only. Not investment advice.